Back to Semaglutide research
semaglutide glp 1 agonist rct 2019-10-07 ClinicalTrials

Semaglutide 2.4mg Weekly Shows Promise for Adolescent Weight Management

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Background

The global prevalence of obesity and overweight among adolescents is a growing public health crisis, contributing to significant long-term health complications. Despite the urgent need, effective and safe pharmacological interventions specifically tailored for this younger demographic remain limited. This randomized, placebo-controlled trial directly addresses this gap by investigating the efficacy and safety of semaglutide 2.4 mg once weekly in adolescents with overweight or obesity.


semaglutide glp 1 agonist dose mentioned protocol relevant
Source: clinicaltrials:NCT04102189 · Ingested 2026-04-14 · Digest: gemini-2.5-flash